A pharmacist has issued a warning over using nasal spray products when you've got ... isotonic saline is gentle for daily use. Whereas hypertonic solutions help to relieve congestion, but can ...

Atzumi combines a proprietary advanced powder and device technology to simplify nasal delivery of dihydroergotamine for acute treatment of migraine.

The FDA has expanded the approval of Valtoco (diazepam nasal spray) to include treatment of seizure clusters in patients aged 2 to 5 years.

For five years, the clinical-stage pharmaceutical company has developed Enbumyst, a nasal spray intended to remove excess ...

The Food and Drug Administration (FDA) has approved Atzumi ™ (dihydroergotamine) nasal powder for the acute treatment of migraine with or without aura in adults.

DHE is a migraine-specific acute medication first approved in 1946. The FDA's approval of the nasal powder formulation, ...

An alternative, nasal spray, formulation has been developed that demonstrates good efficacy, high tolerability and a very fast onset of action. This study assessed the pharmacokinetics and ...

The recommended dose of Atzumi is 5.2mg, the contents of 1 nasal device, administered into 1 nostril. The Food and Drug Administration (FDA) has approved Atzumi ™ (dihydroergotamine) nasal ...

Unlike older medications that target serotonin – a “feel-good” chemical in the brain – the ketamine-based nasal spray works ...

Topical deep delivery of corticosteroids into the sinonasal cavity improves symptoms and sleep in patients with chronic rhinosinusitis.

Previously called STS101, the company said Wednesday that the drug’s brand name is Atzumi and is indicated for acute migraine ...

AstraZeneca has failed in its bid to get US approval for its IL-5 inhibitor Fasenra as a treatment for chronic rhinosinusitis in people with nasal polyps, after the FDA rejected its marketing ...